The dosage in humans is currently 215 mg/m2, which is now above the expected efficacy window of 100 to 200 mg/m2. The qui valency dosage conversions are only used for determining the starting dose in human escalation studies. They are inaccurate for predicting efficacy values, and that inaccuracy in conversion gives numbers 2 to 3 times those seen later in human trials.
News 
Market Data 
Discover 
